Regulatory basis for the safety assessment of nanotechnology-based drug products

Authors

  • Juliana Palermo Tobler Programa de Pós-Graduação Profissional em Gestão, Pesquisa e Desenvolvimento na Indústria Farmacêutica, Farmanguinhos, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil / GlaxoSmithKline, Rio de Janeiro, RJ, Brasil Author https://orcid.org/0000-0003-0315-0584
  • Helvécio Vinícius Antunes Rocha Farmanguinhos, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil Author http://orcid.org/0000-0002-9624-6405

DOI:

https://doi.org/10.22239/2317-269X.01358

Keywords:

Nanomedicine, Safety, Toxicology, Regulation, Anvisa

Abstract

Introduction: Nanotechnology is a transdisciplinary technology that is being developed and applied in several areas, including health, especially in terms of therapy and diagnosis. However, the relationship between some of their physicochemical properties and their toxicological effects remains unclear. Therefore, it is necessary to understand whether the regulatory requirements, in terms of toxicological evaluation, for the registration of a nanotechnology-based drug, are able to identify the possible risks arising from this new technology. Objective: To compare the regulatory approach of US Food and Drug Administration (FDA), European Medicines Agency (EMA) and Brazilian Health Regulatory Agency (Anvisa) with respect to nanomedicine evaluation compared to conventional drugs evaluation. Method: Qualitative bibliographic research was performed in different databases and regulatory agencies websites. Results: Many limitations of the currently recommended tests have been demonstrated, and several are under review for better adaptation to the effect that may suffer by the evaluated nanoparticles themselves. Conclusions: Toxicological tests currently recommended by the regulatory agencies of the United States of America, the European Union and Brazil, although aligned, are not specific for the evaluation of nanomedicines.

Downloads

Download data is not yet available.

Author Biographies

  • Juliana Palermo Tobler, Programa de Pós-Graduação Profissional em Gestão, Pesquisa e Desenvolvimento na Indústria Farmacêutica, Farmanguinhos, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil / GlaxoSmithKline, Rio de Janeiro, RJ, Brasil

    Bachelor's Degree in Pharmacy from the Federal University of Rio de Janeiro (UFRJ), with general qualification from Gama Filho University and certification in Ethics and Good Clinical Practices by the Brazilian Society of Clinical Research Professionals. Experience in Research and Development in the industrial pharmaceutical area (GlaxoSmithKline), working in the monitoring, implementation and strategic review of international clinical studies, mainly in the oncology area. He is currently working in the field of oncology in Latin America at GlaxoSmithKline.

  • Helvécio Vinícius Antunes Rocha, Farmanguinhos, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil

    Bacharel em Farmácia pela Universidade Federal de Juiz de Fora, com especialização em Tecnologia Industrial Farmacêutica e Doutorado em Ciência e Tecnologia de Polímeros, ambos pela Universidade Federal do Rio de Janeiro. Tem experiência em P&D na área farmacêutica, tanto acadêmica quanto industrial, trabalhando principalmente em novos sistemas de liberação de fármacos, tecnologia farmacêutica, pré-formulação e nanotecnologia. É docente permanente do Programa de Pós-Graduação em "Pesquisa Translacional em Fármacos e Medicamentos" e do Programa Profissional em "Gestão, Pesquisa e Desenvolvimento na Indústria Farmacêutica", e também do Curso de Especialização em Tecnologias Industriais Farmacêuticas, todos de Farmanguinhos. Atualmente é tecnologista em saúde pública da Fundação Oswaldo Cruz, onde coordena o Laboratório de Micro e Nanotecnologia (LMN) de Farmanguinhos, a Plataforma de Nanotecnologia Farmacêutica e a Fio-Nano (Iniciativa em Nanotecnologia da Fiocruz).

Published

2020-05-28

Issue

Section

Articles

How to Cite

Regulatory basis for the safety assessment of nanotechnology-based drug products. (2020). Health Surveillance under Debate: Society, Science & Technology , 8(2), 64-74. https://doi.org/10.22239/2317-269X.01358

Similar Articles

1-10 of 304

You may also start an advanced similarity search for this article.